Genematrix
진매트릭스 · 109820
Industrials Commercial Services · KOSDAQ
Market cap US$24.6M (₩33.9B)
Overview
Genematrix develops diagnostic test kits that detect infectious diseases, including sexually transmitted infections, tuberculosis, human papillomavirus, respiratory infections, and acute gastroenteritis, by analysing genetic material from a patient sample.
Its products are used in clinical and laboratory settings, and it also has vaccine and cancer-immunotherapy programmes in development. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core commercial business centres on its NeoPlex product line, which can test for multiple pathogens simultaneously in a single run using proprietary molecular-detection technologies it has developed in-house.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$7.1M
- FY2024US$7.3M
- FY2025US$7.7M
Operating profit
- FY2023−US$1.8M
- FY2024−US$1.2M
- FY2025−US$492.1K
Net income
- FY2023−US$648.5K
- FY2024−US$2.7M
- FY2025−US$1.3M
Key ratios (FY2025)
Price charts coming soon
Interactive price history isn't here yet. Would you use it?